US Grants India 0% Tariff Waiver on Select Specialty Drugs and Pharmaceutical Ingredients
The US India pharma tariff waiver has placed India among 20 jurisdictions eligible for a zero per cent tariff rate on certain specialty pharmaceutical products and associated ingredients imported into the United States.
The US Commerce Department published the eligibility framework as Washington prepares to impose a 100% tariff on certain patented pharmaceutical imports and associated ingredients. The exemption covers specific categories of medicines, including treatments for rare diseases and fertility-related products.
India Among 20 Jurisdictions Eligible for Zero Tariff
India is one of 20 eligible jurisdictions listed by the US Commerce Department for the specialty-pharmaceutical tariff adjustment.
The list includes Argentina, Bangladesh, Cambodia, Ecuador, El Salvador, the European Union, Guatemala, India, Indonesia, Japan, Jordan, Malaysia, North Macedonia, South Korea, Switzerland and Liechtenstein, Taiwan, Thailand, the United Kingdom and Vietnam.
The zero-tariff treatment applies to qualifying products from these jurisdictions under the conditions established by the Commerce Department.
For Indian pharmaceutical exporters, the measure provides an exemption from the new tariff burden for eligible specialty medicines and their associated ingredients.
What Products Are Covered?
The Commerce Department’s September 23 Federal Register notice identifies several categories that can qualify for the 0% tariff rate.
These include:
- Drugs where all approved indications are designated as orphan or rare-disease treatments
- Nuclear medicines
- Plasma-derived therapies
- Fertility drugs
- Cell therapy products
- Gene therapy products
- Antibody-drug conjugates
- Certain medical countermeasures related to chemical, biological, radiological and nuclear threats
- Animal-health pharmaceutical products
Associated pharmaceutical ingredients can also qualify under the framework when the applicable conditions are met.
Rare-Disease and Fertility Medicines Get Special Treatment
The exemption is particularly relevant to medicines addressing conditions for which treatment options can be limited.
Orphan drugs are medicines designated for rare diseases or conditions under US law. The Commerce Department’s rules specifically define qualifying orphan drugs for purposes of determining eligibility for the zero tariff rate.
Fertility drugs are also explicitly included among the categories eligible for the tariff adjustment.
The policy therefore covers several specialized areas of pharmaceutical treatment rather than providing a blanket exemption for all medicines imported from India.
India Still Faces Broader US Pharma Tariff Measures
The tariff waiver should not be interpreted as a complete exemption for India’s pharmaceutical exports to the United States.
The Commerce Department’s framework applies to specific categories and qualifying products. It was introduced as part of the implementation of President Donald Trump’s April 2026 proclamation concerning pharmaceutical and pharmaceutical-ingredient imports.
That proclamation established a 100% tariff on certain patented pharmaceutical products and associated ingredients. The Federal Register notice specifies that the Section 232 pharmaceutical tariffs do not apply to generic pharmaceutical products and associated ingredients.
As a result, the new 0% rate for qualifying specialty products operates within a broader tariff framework rather than replacing it.
Why the Waiver Matters for Indian Pharma Companies
The United States is an important export market for India’s pharmaceutical industry, particularly for generic medicines and pharmaceutical ingredients.
A zero tariff on qualifying specialty products can help eligible Indian manufacturers avoid an additional import cost that would otherwise affect the landed price of their products in the US market.
For companies supplying specialized medicines, the tariff treatment can also provide greater clarity about the cost of serving US customers.
The actual benefit, however, will depend on whether individual products satisfy the Commerce Department’s detailed eligibility requirements.
Trade and Security Framework Is Part of the Eligibility
The US Commerce Department says qualifying specialty pharmaceutical products can receive the zero tariff rate when they are products of a jurisdiction that has a current or forthcoming trade and security framework agreement with the United States, or when they meet an urgent US health need.
The 20 jurisdictions listed in the notice are eligible under the first route, subject to the product-specific conditions established by the rules.
Companies can also request Commerce approval for specialty pharmaceutical imports that meet an urgent US health need.
Companies Can Seek Approval for Urgent Health Needs
The Commerce Department has established a process through which companies can request zero-tariff treatment for qualifying pharmaceutical products that meet an urgent US health need.
Applications must provide information including the product’s classification, active ingredient, category, country of origin, importer and manufacturer details, along with an explanation of the health need.
Companies are expected to provide information such as the disease being treated, available alternative therapies, the number of US patients using the product and whether the medicine is available in other jurisdictions.
Generic Medicines Remain Outside the New Section 232 Tariff
One important aspect of the US policy is the treatment of generic medicines.
According to the Commerce Department notice, the Section 232 pharmaceutical tariffs do not apply to generic pharmaceutical products and associated ingredients. This means the latest tariff changes primarily affect specific patented pharmaceutical products and ingredients covered by the proclamation.
This distinction is important for Indian pharmaceutical companies because India has a large presence in the US generic-drug market.
The latest waiver therefore adds another layer of differentiation between generic medicines and specialized or patented pharmaceutical products.
What the Policy Means for US Drug Supply
The tariff exemptions also have implications for US pharmaceutical supply chains.
Specialty medicines, fertility treatments, rare-disease drugs and advanced therapies can involve complex manufacturing processes and globally distributed supply chains.
Keeping certain products at a zero tariff rate can reduce the risk that new import duties immediately increase costs for medicines that may have limited alternatives.
The Commerce Department has also created a zero-tariff provision for certain pharmaceutical products and associated ingredients used solely for clinical trials, research and development or other non-commercial applications, subject to the applicable classifications.
US-India Pharmaceutical Trade Gets a Targeted Relief
The decision provides targeted relief to India rather than a broad pharmaceutical tariff exemption.
Indian companies exporting qualifying specialty drugs and ingredients can benefit from the 0% tariff treatment, while products outside the designated categories remain subject to the applicable US trade rules.
For the Indian pharmaceutical sector, the development is significant because it preserves tariff-free access for a defined group of products even as Washington introduces broader measures aimed at reshaping pharmaceutical imports and encouraging domestic manufacturing.
The impact will ultimately depend on which Indian products qualify and how companies and US importers apply the new rules.
Frequently Asked Questions
1. What is the US India pharma tariff waiver?
It is a US policy allowing a 0% tariff rate on certain qualifying specialty pharmaceutical products and associated ingredients from India and 19 other eligible jurisdictions.
2. How many jurisdictions received the tariff exemption?
The US Commerce Department listed 20 jurisdictions, including India, as eligible for the tariff adjustment.
3. Which Indian medicines can receive the 0% tariff?
Eligible categories include certain rare-disease or orphan drugs, fertility drugs, nuclear medicines, plasma-derived therapies, cell and gene therapies, antibody-drug conjugates and other designated specialty pharmaceutical products.
4. Are pharmaceutical ingredients also covered?
Yes. Associated pharmaceutical ingredients can qualify for the zero tariff rate when they meet the applicable requirements.
5. Does the waiver cover all Indian pharmaceutical exports?
No. The measure is targeted at specified pharmaceutical categories and qualifying products. It is not a blanket tariff exemption for all medicines exported from India.
6. Are generic medicines subject to the new Section 232 pharma tariff?
The Commerce Department says the Section 232 pharmaceutical tariffs do not apply to generic pharmaceutical products and associated ingredients.
7. Why are rare-disease medicines included?
The US framework specifically provides for a zero tariff rate on drugs where all approved indications are designated as orphan, meaning they are intended for certain rare diseases or conditions.
8. Are fertility drugs included in the exemption?
Yes. Fertility drugs are explicitly listed among the specialty pharmaceutical categories eligible for the zero tariff rate under the framework.
9. Can companies request an exemption for other medicines?
Companies can request Commerce approval for qualifying pharmaceutical products that meet an urgent US health need, subject to the application process and requirements established by the department.
10. What does the waiver mean for Indian pharma companies?
For companies whose products qualify, the 0% tariff rate can help avoid the additional import duty that would otherwise apply under the relevant pharmaceutical tariff framework, potentially supporting continued access to the US market.
